Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cell Transplant and Aldesleukin for Non-M3 AML in First Remission
NCT00534469Phase 2Completed
- Sponsor
- City of Hope
- Start
- Feb 2000
- Primary completion
- Dec 2022
- Modality
- Cytokines & Interferons, Small Molecules
01
Overview
A Phase 2 trial of busulfan, etoposide, aldesleukin in acute myeloid leukemia (AML), sponsored by City of Hope. Started Feb 2000; status: completed.
02
Drugs
busulfanetoposidealdesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00534469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00534469.